Shares of Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) have been assigned an average recommendation of “Hold” from the twelve ratings firms that are currently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, six have assigned a hold recommendation and five have assigned a buy recommendation to the company. The average twelve-month price objective among analysts that have covered the stock in the last year is $8.42.
Several analysts have recently weighed in on the company. ValuEngine downgraded Keryx Biopharmaceuticals from a “hold” rating to a “sell” rating in a report on Friday, June 2nd. Maxim Group boosted their target price on Keryx Biopharmaceuticals from $7.00 to $9.00 and gave the company a “buy” rating in a report on Monday, May 15th.
A number of hedge funds have recently bought and sold shares of KERX. Norges Bank bought a new stake in Keryx Biopharmaceuticals during the fourth quarter valued at approximately $9,973,000. Deerfield Management Co. bought a new stake in Keryx Biopharmaceuticals during the fourth quarter valued at approximately $7,568,000. Old West Investment Management LLC increased its stake in Keryx Biopharmaceuticals by 295.4% in the first quarter. Old West Investment Management LLC now owns 828,914 shares of the biopharmaceutical company’s stock valued at $5,106,000 after buying an additional 619,285 shares in the last quarter. State Street Corp increased its stake in Keryx Biopharmaceuticals by 20.1% in the first quarter. State Street Corp now owns 3,479,370 shares of the biopharmaceutical company’s stock valued at $21,432,000 after buying an additional 582,624 shares in the last quarter. Finally, Vanguard Group Inc. increased its stake in Keryx Biopharmaceuticals by 4.6% in the first quarter. Vanguard Group Inc. now owns 6,848,748 shares of the biopharmaceutical company’s stock valued at $42,188,000 after buying an additional 302,986 shares in the last quarter. 62.32% of the stock is owned by hedge funds and other institutional investors.
TRADEMARK VIOLATION NOTICE: “Keryx Biopharmaceuticals, Inc. (KERX) Given Consensus Recommendation of “Hold” by Analysts” was published by WKRB News and is the property of of WKRB News. If you are viewing this article on another site, it was illegally copied and reposted in violation of international trademark and copyright law. The legal version of this article can be accessed at https://www.wkrb13.com/markets/2228843/keryx-biopharmaceuticals-inc-kerx-given-consensus-recommendation-of-hold-by-analysts.html.
Keryx Biopharmaceuticals (NASDAQ:KERX) traded down 3.80% during midday trading on Friday, reaching $5.83. The company’s stock had a trading volume of 3,780,356 shares. Keryx Biopharmaceuticals has a 1-year low of $4.03 and a 1-year high of $7.80. The stock’s 50-day moving average price is $6.38 and its 200 day moving average price is $5.81. The firm’s market capitalization is $632.36 million.
Keryx Biopharmaceuticals (NASDAQ:KERX) last posted its earnings results on Thursday, May 4th. The biopharmaceutical company reported ($0.21) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.18) by $0.03. Keryx Biopharmaceuticals had a negative net margin of 387.12% and a negative return on equity of 1,122.28%. The firm had revenue of $11.82 million during the quarter, compared to analysts’ expectations of $10.19 million. During the same period in the previous year, the firm posted ($0.39) earnings per share. The firm’s revenue for the quarter was up 73.2% on a year-over-year basis. Equities analysts anticipate that Keryx Biopharmaceuticals will post ($0.69) EPS for the current fiscal year.
About Keryx Biopharmaceuticals
Keryx Biopharmaceuticals, Inc is a biopharmaceutical company focused on the development of medicines for people with renal disease. The Company is engaged in the manufacture, development and commercialization of products for use in treating human diseases. Its marketed product, Auryxia (ferric citrate), which is an orally available, absorbable, iron-based medicine is approved in the United States for the control of serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2228843/keryx-biopharmaceuticals-inc-kerx-given-consensus-recommendation-of-hold-by-analysts.html
Receive News & Ratings for Keryx Biopharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Keryx Biopharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.